way may serve as therapeutic targets for treatment of intractable pain, neuronal injury, androgen-independent prostate cancer, cardiovascular diseases, etc.
receptor potential ankyrin-1 (TRPA1) channels, large conductance Ca 2+ -activated K + (BK) channels, cystic fibrosis transmembrane conductance regulator Cl -channels, NMDA receptors, in addition to transcription factors and protein kinases [2, 3, 6, 7] . In the nociceptor neurons, H 2 S enhances the function of Ca v 3.2 T-type Ca 2+ channels [8] [9] [10] [11] [12] and TRPA1 channels [13, 14] , leading to the neuronal excitation and then pain sensation or hyperalgesia/allodynia [3, 7, 15] . We have also shown that the acceleration of Ca v 3.2 channel activity by exogenous H 2 S causes neuritogenesis and neuronal differentiation in NG108-15 cells [9, 10, 16] , and that the endogenous H 2 S/ Ca v 3.2 pathway regulates secretory function in the neuroendocrine-like differentiated human prostate cancer LNCaP cells [17] . Here, we thus focus on the roles of Ca v 3.2 T-type Ca 2+ channels and H 2 S in pain processing, neuronal differentiation and neuroendocrine secretion.
H 2 S-Mediated Functional Acceleration of T-Type Calcium Channels
Low-voltage-activated Ca 2+ channels, known as Ttype Ca 2+ channels, are classified into 3 different types, Ca v 3.1, Ca v 3.2 and Ca v 3.3 [18] . Unlike high-voltage-activated (HVA: L-, N-, P/Q-, and R-types) Ca 2+ channels, T-type Ca 2+ channels appear to consist of only α1 subunit and do not require coassembly with auxiliary subunits such as α2δ, β and γ that are essential for HVA Ca 2+ channels. Under the physiological conditions, T-type Ca 2+ channels are activated by depolarization near a resting membrane potential, thereby regulating neuronal excitability. There is evidence for the involvement of Ttype Ca 2+ channels in secretion of hormones or neurotransmitters, muscle contraction and cell differentiation or proliferation [19, 20] . Among 3 isoforms of T-type Ca 2+ channels, Ca v 3.2 appears to mediate some of biological actions of H 2 S. H 2 S donors, NaHS and Na 2 S, facilitate T-type Ca 2+ channel currents (T-currents) in NG108-15 (mouse neuroblastoma × rat glioma) cells, isolated dorsal root ganglion (DRG) neurons and neuroendocrine-like differentiated human prostate cancer LNCaP cells that naturally express Ca v 3.2 [9] [10] [11] 17] , and also in Ca v 3.2-transfected HEK293 cells [21] . The T-currents are suppressed by DL-propargylglycine (PPG), a CSE inhibitor, in neuroendocrine-differentiated LNCaP cells and Ca v 3.2-transfected HEK293 cells that abundantly express CSE, an H 2 S-forming enzyme, suggesting that the function of Ca v 3.2 is positively regulated by endogenous H 2 S in those cells [17, 21] . These findings are in agreement with recent evidence from an independent group that endogenous H 2 S formed by CSE following hypoxia and H 2 S donor-derived exogenous H 2 [24] . The NaHS-induced facilitation of T-currents in NG108-15 cells is also attenuated by ascorbic acid [10] . There is a conflicting report showing that NaHS at low and high concentrations suppresses and enhances T-currents, respectively, in Ca v 3.2-transfected HEK293 cells [12] , although the physiological significance of the H 2 Sinduced T-current attenuation, if any, remains unclear. Nevertheless, we have never detected such inhibitory effect of H 2 S donors in an extensive concentration range on T-currents in HEK293 cells transfected with Ca v 3.2 or other cells that naturally express Ca v 3.2 [7, 9-11, 16, 17, 21] .
Roles of Endogenous H 2 S and T-Type Calcium Channels in Pain Processing
The concentrations of endogenous H 2 S in the mammalian tissues are regulated by 3 principal H 2 S-producing enzymes, CSE, CBS, and 3-MST/CAT. It has been reported that CSE and CBS are upregulated in inflammatory conditions such as sepsis, pancreatitis and cystitis in rats or mice [25] [26] [27] [28] . On the other hand, Ca v 3.2 targeted by H 2 S is upregulated de novo or functionally in the DRG and/or spinal cord in laboratory animals with surgically induced neuropathic pain [15, [29] [30] [31] [32] [33] . In mice or rats, intraplantar and intracolonic administration of NaHS, an H 2 S donor, evokes mechanical hyperalgesia/allodynia and visceral nociceptive behavior accompanied by re- 198 ferred hyperalgesia, respectively, which are blocked by Ttype Ca 2+ blockers or gene silencing of Ca v 3.2 [8, 11, 29, 34, 35] . In the mice with cerulein-induced pancreatitis and with cyclophosphamide-induced cystitis, CSE protein is markedly upregulated in the pancreas and bladder, respectively, and the concomitant pancreatic and bladder pain are abolished by a CSE inhibitor or distinct T-type Ca 2+ channel blockers, and by knockdown of Ca v 3.2 in DRG by intrathecal administration of the Ca v 3.2-targeting antisense oligodeoxynucleotide [26, 27, 36] . The CSE inhibitor, T-type Ca 2+ channel blockers and knockdown of Ca v 3.2 also suppress the neuropathic hyperalgesia induced by L5 spinal nerve injury in rats, and upregulation of Ca v 3.2 channels, but not CSE, at protein levels are detectable in the DRG following the development of neuropathy [31] . Paclitaxel-evoked painful neuropathy in rats is also suppressed by the inhibitors of CSE and T-type Ca 2+ channels, while the expression levels of CSE and Ca v 3.2 proteins in the DRG and hindpaws do not change after paclitaxel treatment [37] . In both type I (streptozotocin (STZ) injection-induced diabetes) and type II (leptin-deficient (ob/ob) mice) diabetic mouse models, the diabetic neuropathy is considered to involve the upregulation of Ca v 3.2 T-type Ca 2+ channels in small-medium size DRG neurons [38, 39] . There is also evidence that hyperalgesia/allodynia accompanying STZ-induced diabetic neuropathy in rats is suppressed by systemic administration of inhibitors of CSE (PPG) or CBS (hydroxylamine) [40] . The increased production of endogenous H 2 S by CSE or CBS and possibly concomitant enhancement of Ca v 3.2 channel activity would thus appear to be involved in diabetic neuropathy. Together, studies on the roles of the endogenous H 2 S/Ca v 3.2 pathway in pain processing might unveil novel therapeutic avenues for treatment of intractable pain including neuropathic and visceral pain ( fig. 1 [9, 10] . The NaHS-induced neuritogenesis is not affected by inhibition of other ion channels known as possible targets for H 2 S, K ATP , TRPA1 and HVA Ca 2+ channels [10] . The activity of Src kinase appears to be required for the NaHS-evoked neuronal differentiation of NG108-15 cells [10] .
Roles of Endogenous H 2 S and T-Type Calcium Channels in Neuronal and Neuroendocrine Secretion
H 2 S appears to regulate secretory function in the pancreas, hypothalamus and pituitary gland; for example, H 2 S decreases insulin secretion via activation of K ATP channels in rat insulinoma INS-1E cells or inhibition of L-type Ca 2+ channels in mouse pancreatic β cells [47, 48] , enhances 5-hydroxytryptamine release via activation of TRPA1 channels in clonal rat pancreatic delta RIN14B cells [49] and reduces the exocytosis of secretory granules via activation of K ATP channels in rat pituitary tumor GH3 cells [50] . Interestingly, T-type Ca 2+ channels trigger Ca 2+ entry during small depolarization around the resting potential and concomitant vesicular exocytosis in the neuronal system, which is essential for synaptic neurotransmitter release at rest [51] . Thus, we next focus on the roles of the endogenous H 2 S/Ca v 3.2 pathway in neuronal or neuroendocrine secretion in neuroendocrinedifferentiated prostate cancer cells, glomus cells in the carotid body, and chromaffin cells in the adrenal medulla [17, 52, 53] .
The H 2 S/Ca v 3.2 Pathway Regulates Neuroendocrine Secretion in Human Prostate Cancer LNCaP Cells
The growth of prostate cancer is androgen-dependent in general, so that the hormone therapy by androgen deprivation or androgen receptor blockade is highly effective. However, the hormone therapy for prostate cancer patients is overridden in several years. Acquisition of the androgen-independent properties of prostate cancer is conceived as a major reason for the development of the hormone therapy tolerance [54] . There is evidence that neuroendocrine-like differentiation of prostate cancer cells contributes to the androgen-independent growth [55, 56] . In androgen-dependent human prostate cancer LNCaP cells, the neuroendocrine-like differentiation is induced by an elevation of intracellular cAMP levels, androgen deprivation or treatment with interleukin-6 in a subpopulation of the cells [57] . The differentiated cells show androgen-independent properties, and secrete the proliferative neuropeptides such as neurotensin and parathyroid hormone-related peptide (PTHrP), which promote the proliferation of surrounding prostate cancer cells [58, 59] . Ca v 3.2 T-type Ca 2+ channels are abundantly expressed in neuroendocrine-like differentiated LNCaP cells, and mediate Ca 2+ -dependent secretion [17, [60] [61] [62] , while the expression of L-type Ca 2+ channels is not detected in those cells [63] .
The protein expression and activity of H 2 S-forming enzymes, CSE and CBS, in the prostate cancer LNCaP cells are much more than those in normal prostatic epithelial RWPE-1 cells [64] . The expression of these enzymes in LNCaP cells increases during neuroendocrinelike differentiation induced by treatment with db-cAMP plus isobutylmethylxanthine (IBMX), a phosphodiesterase inhibitor [17] . The H 2 S donors, NaHS and Na 2 S, further enhance the increased T-currents dependent on the upregulated Ca v 3.2 in the neuroendocrine-like differentiated LNCaP cells. Interestingly, the increased T-currents in the neuroendocrine-like LNCaP cells are partially attenuated by the treatment with the CSE inhibitors, PPG and β-cyano-L-alanine, but not a CBS inhibitor aminooxy acetic acid (AOAA), suggesting that endogenous H 2 S produced by the upregulated CSE, but not CBS, enhances the activity of the overexpressed Ca v 3.2 channels in neuroendocrine-like LNCaP cells. In parallel with the upregulation of Ca v 3.2 channels, spontaneous Ca 2+ -dependent secretion increases following neuroendocrine-like differentiation with db-cAMP plus IBMX in LNCaP cells [60] . The increased spontaneous secretory function in the neuroendocrine-like LNCaP cells is abolished by mibefradil, a T-type Ca 2+ channel blocker, or PPG, but not AOAA, whereas mibefradil does not affect the secretory response in undifferentiated LNCaP cells that do not abundantly express CSE and Ca v 3.2 [17] . Together, it is considered that, in neuroendocrine-differentiated prostate cancer LNCaP cells, H 2 S generated by the upregulated CSE further enhances the channel activity of the upregulated Ca v 3.2 and causes the augmentation of the secretory function ( fig. 2 ). Since the neuroendocrine-like differentiation of LNCaP cells by db-cAMP plus IBMX results in the upregulation of neurotensin and PTHrP, mitogenic neuropeptides [17] , the enhanced secretory function brought about by the CSE/H 2 S/Ca v 3.2 pathway may contribute to the increased secretion of those mitogenic factors in the differentiated cells, leading to androgen-independent proliferation in the surrounding undifferentiated cells ( fig. 2 ). This hypothesis is in agreement with the evidence that the conditioned culture medium from the neuroendocrine-like differentiated LNCaP cells and neurotensin promote mitogenesis of androgen-independent prostate cancer PC3 cells [65] . Therefore, pharmacological inhibition of the CSE/H 2 S/Ca v 3.2 pathway might be beneficial to prevent the acquisition of androgen-independent property of prostate cancer. However, the longterm inhibition of CSE might cause unexpected serious biological events, because endogenous H 2 S plays important physiological roles throughout the mammalian body including the cardiovascular, gastrointestinal and neuronal systems [1, 4] . In addition, CSE contributes to not only L-Cys metabolism to H 2 S and pyruvate, but also Lcystathionine metabolism to L-Cys and α-ketobutyrate [3] , so that the abnormal metabolism of L-Cys or L-cystathionione caused by CSE inhibitors might also limit their therapeutic use. In contrast, the pharmacological blockade of Ca v 3.2 T-type Ca 2+ channels might be suitable for the treatment of prostate cancer. Actually, several blockers of T-type Ca 2+ channel appear to inhibit the proliferation and migration of androgen-independent prostate cancer DU-145 cells [66] . Although there is no report concerning the development of selective blockers of Ca v 3.2 channels, ascorbic acid (vitamin C) and zinc block Ca v 3.2, but not Ca v 3.1 or Ca v 3.3 [23, 24] . Strikingly, it has been reported that the pharmacological dose of ascorbic acid suppresses tumor growth and metastases of implanted hormone-resistant prostate adenocarcinoma cells in rats [67] .
Involvement of the H 2 S/Ca v 3.2 Pathway in the Hypoxia-Induced Catecholamine Secretion in the Carotid Body and Adrenal Medulla
Hypoxia induces Ca 2+ -dependent release of catecholamines (CAs) in glomus cells of the carotid body, an organ sensing arterial blood O 2 concentration, which is essential for controlling the function of respiratory and cardiovascular systems [22] . The hypoxia-induced secretion of CAs is observed also in the adrenal medullary chromaffin cells [52] . It has been reported that CSE, an H 2 S-forming enzyme, is expressed in glomus cells in the carotid body and adrenal medullary chromaffin cells, and that the hypoxia-evoked CA secretion is attenuated in CSE knockout mice or by the treatment with CSE inhibitors, indicating the critical role of endogenous H 2 S formed by CSE in the respiratory and cardiovascular homeostatic control in response to hypoxia [22, 52] . Voltage-gated HVA and Ttype Ca 2+ channels are also expressed in glomus cells of the carotid body [68, 69] , and the hypoxia-evoked elevation of intracellular Ca 2+ concentration and CA secretion in the glomus cells are attenuated by inhibitors of L-type (nifedipine) or T-type (mibefradil and TTA-A2) Ca 2+ channels, or in Ca v 3.2 knockout mice [22, 70] 2+ channels (L-, N-, P/Q-and R-types) [72] . On the other hand, T-type Ca 2+ channels are poorly expressed or absent in adult chromaffin cells, but are functionally expressed in the embryonic and neonatal chromaffin cells [51, 72] . In addition, Ca v 3.2 T-type Ca 2+ channels in adult chromaffin cells are upregulated in response to various long-term stressful stimuli, such as chronic hypoxia, β-adrenergic and high-frequency sympathetic stimulation and exposure to cAMP, and contribute to low-threshold CA secretion [19, 51] . On the other hand, NaHS, an H 2 S donor, induces CA secretion in rat adrenal chromaffin cells [53] . CSE is detected in the chromaffin cells, and upregulated and involved in the hypoxia-evoked CA secretion in response to hypoxia [52] . Collectively, the CSE/H 2 S/Ca v 3.2 pathway may play a role in the hypoxia-evoked CA secretion in adrenal chromaffin cells, as in glomus cells of the carotid body. This hypothesis has yet to be demonstrated by future more in-depth studies.
Conclusion
As described so far, the CSE/H 2 S/Ca v 3.2 T-type Ca 2+ channel pathway plays roles in the pain processing, neuronal differentiation and neuronal or neuroendocrine secretion. Thus, pharmacological inhibition or acceleration of this pathway may be beneficial for treatment of intractable pain, neuronal or axonal injury, prostate cancer and impaired homeostatic regulation of the respiratory and cardiovascular systems.
